Focus on cannabis and psychdelic sectors, small cap, micro cap and mid cap companies
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You're right, hopefully the sector wide decline won't last past today. Sector has been up all week so was due for a red day.
Aurora just announced another bought deal lol 12M units for $125M. Won't have to worry about that with CRON. No dead, unused, "sky", "double diamond" factories to pay for.
The underwriters have agreed to buy 12 million units of the company at US$10.45 per unit. Each unit is comprised of one common share and one half of one common share purchase warrant.
Sean Williams sucks and I've proven him wrong several times over the years. His and MotleyFool's entire view of the cannabis sector has been centered around capacity which is an extremely limited, conservative and ignorant way of looking at the sector. Williams and MF praised companies that spent millions to expand into dead facilities and have laid off hundreds of workers. They praised companies that diluted millions of shares and RS'ed. Meanwhile former CEO Mike Gorenstein and the MO folks have stated many times their focus is on differentiated products and lowest cost cultivation/production. They did not spend millions expanding into dead facilities only to lay off workers months later. They'll most likely never need to do a RS or another raise. Cherry picking and highlighting negatives like noting the lack of US sales is laughable.
MONTHLY PROGRESS REPORT
https://webfiles.thecse.com/201231_Pharmadrug_CSE_Form_7_-_Monthly_Progress_Report_-_December.pdf?SlcTCmxqWsYZewWKQS3DQK7gjdgR7GCK=
Name of Listed Issuer: Pharmadrug Inc. (the “Issuer”).
TradingSymbol: BUZZ
Number of Outstanding Listed Securities: 240,002,183
Date: December 31, 2020
Report on Business
1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose
this fact.
On December 15, 2020, Pharmadrug Inc. (“Pharmadrug”, “We” or the “Company”) provided certain updates following the recent general equity market upswing and the increase in the Company’s volume and share price appreciation. Recent market activity has served to significantly strengthen Pharmadrug's
balance sheet and improve its ability to execute on its current business plan.The market has contributed to increased balance sheet strength is four distinct ways. Firstly, the Company raised in excess of $850,000 by selling marketable securities it owned. Secondly, the Company holds 4.24 million shares of Red Light Holland Corp. (“RLH”) of which it has not yet sold any shares. The Company also holds 4.24 million warrants of RLH exercisable at a price of $0.26 per share. Thirdly, the Company received numerous conversion notices of its outstanding debentures which have a conversion feature at $0.05 per share. As a result, the Company has already seen a material decrease in its outstanding debt. Lastly, the Company had a sizeable amount of $0.05 warrants in the market which had since been exercised. With a large increase in its cash balance at year-end, management plans to use increased cash position to execute on a more aggressive growth plan in Germany and the Netherlands.
The Company is in the final stages of adding additional Medical Cannabis lines and has already started negotiations to add to its product offering to pharmacies narcotics lines outside of the Cannabis space. Management will look to add more salespeople in country and to accelerate activities to add more product lines to build out a larger and more diversified pharmaceutical distribution company, which we expect to include pharmaceutical psychedelic products as they become legally available in Germany. In the Netherlands, the Company is continuing to advance on building out and launching its online psychedelics retail platform. We have also shortlisted locations for a flagship store in Amsterdam. Management will use increased liquidity to accelerate growth plans in 5 follow on cities in the country and has will contemplate strategic moves to vertically integrate and broaden out its psychedelics business model in The Netherlands before expanding into other countries.
2. Provide a general overview and discussion of the activities of management
Pharmadrug is building a European controlled substances company with a focus on medical cannabis and psychedelics:
In the medical cannabis side of business, the Company currently sources and wholesales products to pharmacies in Germany with a strategy to launch and
develop its own brand of cannabis for distribution in Germany and other legal jurisdictions in the European Union (“EU”); and
In the psychedelics domain, the Company intends to utilize a unique twopronged approach: (i) the first approach will be to capitalize on markets in the
Netherlands through consolidation of legalized adult-use psychedelic dispensaries; (ii) secondly, as products get developed and achieve regulatory approval or get legalized in jurisdictions across the Eurozone, the Company will seek to utilize its controlled substance import and distribution license to establish a pharmaceutical psychedelic business.
Medical Cannabis:
Management’s thesis is that the European medical cannabis market will soon command significant attention. Europe is home to more than 740 million people, a population which is more than double that of the United States and Canada combined. Industry analysts expect Europe to be one of the largest consumers of medical cannabis around the world in the coming decade.
As Pharmadrug continues to develop business in Germany, management believes that the Company will see significant growth in 2021. A new sales team
was put in place in late 2019, and to date, it has been executing on a new strategic plan. The Company has grown its Bedrocan business, and the number of
pharmacies in its distribution network had more than tripled to over 300. However, as Bedrocan’s supply is becoming increasingly limited, it has served as
an impediment to growth. The third quarter of 2020 saw more volatility in sales volume as the Company frequently ran out of inventory and had to wait longer
for smaller shipments from the Netherlands. Demand is currently outstripping supply. The Company believes it already has enough of a distribution network
to achieve profitability, but needs to secure more sources to satisfy demand.
In order to address short-term needs for additional supply, the Company had decided to secure a second wholesale source of cannabis directly from another
LP for products under their brand. While negotiations with the first LP ended without an agreement, the Company is now in talks with another major North
American LP and is optimistic it can secure an agreement soon. The Company has also been working on sourcing product from within the Eurozone. Management was in advanced discussions with two emerging LPs operating out of Denmark, but is still trying to determine if they can produce the type of end
product that suits the Company’s needs. The Company is also in advanced discussions with producers in both Spain and Portugal, and is hopeful it can
source product from one of those countries in the short term.
In order to take advantage of the Company’s full narcotics license and capabilities, management is actively sourcing products to distribute outside of the
cannabis space. We believe our growing pharmacy network would be underutilized by merely focusing on cannabis and the path to significant growth and
profitability would be more easily achieved with a broadened product offering. We will make certain to only take on product lines that compliment a cannabis
offering. We have already began discussions with suppliers within Europe and have been consulting with pharmacies in our network to ascertain which products they believe could support a new supply source.
Psychedelics:
The Company intends to utilize a unique two-prong approach. The first, with Super Smart, will be to capitalize on markets in the Netherlands through the
development of an adult-use Smart Shop brand, brick and mortar chain and an online retail platform. Secondly, in Germany and across the Eurozone, the
Company will seek to use Pharmadrug GmbH’s controlled substance import and distribution license to build a pharmaceutical psychedelics business as
jurisdictions in the EU legalize psychedelics and pharmaceutical psychedelics pass through clinical testing. Pharmadrug GmbH recently passed its EuGMP
inspection and has secured its certification for another three years. This gives the Company the ability to third party source narcotics and package them under its own brand.
Super Smart took effective control of its first smart shop on October 1, 2020. The Smart Shop is located in the Town of Tiel, a municipality in central Netherlands, and will serve as an initial platform for Super Smart to build out and refine its new smart shop vision and a springboard to develop its brand and operations. Over the past few months, Super Smart has laid much of the groundwork needed to purchase the first store and as such began developing
the organizational structure that will enable the company to make several more purchases and scale up more efficiently. The work includes hiring a country
manager, setting up corporate structures, template legal contracts, financial controls and bank accounts.
For several strategic reasons, the Company entered into the RLH Share Exchange with RLH. The two companies recognize the complimentary nature of
their respective business models in the Dutch psychedelic market and will seek to collaborate on strategic initiatives. RLH’s strategy to be a premier grower of psychedelic truffles with microdose packaging fits well with Super Smart’s vision of elevating the Smart Store experience by introducing new products and an educational approach. Together, the two companies plan to develop and foster a new market segment that seeks to use psilocybin to either attempt to potentially treat medical conditions holistically or to increase cognitive performance. On a combined basis, we can better execute on educating the market and increasing the profile of psychedelics and psilocybin in the Netherlands at first followed by other markets as they legalize.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
Pharmadrug plans to grow its distribution platform beyond Germany into other EU countries. Pharmadrug GmbH, its German subsidiary, is a Schedule I Narcotics distributor which allows the German business to export GMP medical cannabis to other EU countries as and when those countries legalize cannabis.The latest supply agreements with Canada House Wellness Group Inc., My Green Fields Ltd. and NMC will allow Pharmadrug to provide its German distribution base with additional supply under its own Cannabion brand in a market that remains short in supply. It will also provide access to oils and extracts to serve German pharmacies as well as to other markets in the Eurozone. The Company has recently expanded its sales efforts in effort to enable broader distribution.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
None noted
5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
None noted.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
None noted.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.
None noted.
8. Describe the acquisition of new customers or loss of customers.
None noted.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
None noted.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
None noted.
11. Report on any labour disputes and resolutions of those disputes if applicable.
None noted.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
None noted.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
None noted.
14. Provide details of any securities issued and options or warrants granted.
Security Number Issued Details of Issuance Use of Proceeds (1)
Common shares 12,400,000 Issuance on conversion of debentures into units (1 share and ½ warrant). N/A
Warrants 6,200,000 Issuance on conversion of debentures into units (1 share and ½ warrant). N/A
Common shares 400,000 Issuance of units via exchange N/A
Common shares 23,996,805 Issuance on exercises of warrants $1,199,840
15. Provide details of any loans to or by Related Persons.
None noted.
16. Provide details of any changes in directors, officers or committee members.
None noted.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends. For more information related to certain risks and uncertainties that are inherent to the Company’s industry, please refer to the “Risk Factors” section of the Management’s Discussion and Analysis filed quarterly on SEDAR.
In addition, on January 30, 2020, the World Health Organization declared that the recent COVID-19 outbreak was a global health emergency, recognizing that the disease represents a risk outside of China, where it emerged in the last couple of months. Companies across various industries could be impacted materially by the coronavirus.
COVID-19’s known and unknown impact on earnings, costs, employees, supply chains, customers and other stakeholders, as well as other business matters,
may be material for the Issuer, and may have a material impact on the Issuer’s gross earnings, net earnings and other business matters. Environmental, social and governance factors may also impact the Issuer’s operations in the near future.
PharmaDrug Announces LOI to Acquire Sairiyo
Therapeutics Inc.
https://webfiles.thecse.com/sedar_filings/00032549/2101120505348964.pdf
Toronto, Ontario--(Newsfile Corp. - January 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink:
LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the
development and commercialization of controlled-substances and natural medicines such as
psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered
into a binding letter of intent (the "LOI"), dated January 11, 2021, to acquire Sairiyo Therapeutics Inc.
("Sairiyo") (the "Acquisition").
Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of
naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain
European Medicines Evaluation Agency and U.S. Food and Drug Administration ("FDA") approval.
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed
and reformulated naturally-derived compound for the potential treatment of cancer, neurological,
inflammatory and infectious diseases. Cepharanthine is a natural product and an approved drug used for
more than 70 years in Japan to treat a variety of acute and chronic diseases. In clinical research,
Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory,
immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo has an exclusive license
from a research and development organization to develop and commercialize reformulated
Cepharanthine for all diseases and exclusive rights to the patent, method of manufacturing, clinical
supply, pre-clinical data and know-how to support FDA clinical trials. Sairiyo has applied for FDA orphan
drug designation of Cepharanthine in certain cancer indications and is also leveraging its expertise in
drug discovery by evaluating novel uses of psychedelic and cannabinoid compounds for unmet medical
needs.
"The proposed acquisition of Sairiyo Therapeutics builds on our foundation of developing and
commercializing controlled substances and naturally-derived medicines in Europe while expanding our
opportunities with an FDA focused strategy and leveraging Sairiyo's expertise in the discovery and
development of novel uses and reformations of naturally-derived compounds for significant clinical unmet
needs, thus paving the way for PharmaDrug to become a fully-integrated specialty pharmaceutical
company," said Daniel Cohen, Chairman and CEO of PharmaDrug.
Under the terms of the LOI, PharmaDrug proposes to acquire all of the issued and outstanding shares of
Sairiyo in consideration for the issuance of an aggregate of 75,000,000 units of PharmaDrug ("Units").
Each Unit will be comprised of one common share of PharmaDrug and one common share purchase
warrant (a "Warrant") of PharmaDrug. Each Warrant will entitle the holder thereof to acquire one
common share in the capital of PharmaDrug at any time on or before the 18 month anniversary of the
issuance of the Warrants at an exercise price of $0.10 per share. Following completion of the
transaction Sairiyo will be a wholly-owned subsidiary of the Company.
Completion of the transaction is subject to customary closing conditions, including completion of due
diligence, negotiation of definitive agreements and receipt of all necessary approvals. If such conditions
are not satisfied it is possible that the proposed transaction will not be completed on the terms set forth
herein or at all. The parties anticipate completing the definitive agreements within the next 30 days, and
anticipate that the transaction will be completed in the first quarter of 2021.
We should see movement in the sector after next week's election. The sector will be more optimistic as a whole once the US sets a path to decriminalization/legalization and better regulations. The legislation is ready to go. Until then, hold on. Happy New Year!
I agree...almost there!
The market has been saying otherwise!
Big details coming. Harrington's excited!
Did you hear something I didn't? Because Optec told everyone the news didn't come from them. They never denied. Must've missed it when they said it was fake.
I'd advise everyone to hold, BIG details coming!
No, you're very likely WRONG again.
Folks should hold, BIG details coming. Harrington's probably excited about a Walmart/Target deal to announce.
I think it's obvious that you're WRONG!
WRONG!
Pharmadrug Provides Corporate Update and Balance Sheet Status
Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC Pink:
LMLLF) ("PharmaDrug" or the "Company") is pleased to provide an update to the status of its balance
sheet following the recent general equity market upswing and the increase in PharmaDrug's volume and
share price appreciation.
Recent market activity has served to significantly strengthen PharmaDrug's balance sheet and improve
its ability to execute on its current business plan. The market has contributed to increased balance sheet
strength is four distinct ways. Firstly, PharmaDrug was able to raise in excess of $850,000 by selling
marketable securities that the Company valued on its Q3 financials at $200,000, due to a subsequent
increase in the value of the shares. Secondly, the Company holds 4.24 million shares of Red Light
Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC:TRUFF), of which it has not yet sold any shares. The
Company also holds 4.24 million warrants of Red Light Holland exercisable at a price of $0.26 per
share. Thirdly, the Company is now receiving conversion notices of its outstanding debentures which
have a conversion feature at $0.05 per share. As a result, the Company has already seen a material
decrease in its outstanding debt since Q3 financials. We will update the market on the debenture
principal outstanding prior to year-end. Lastly, the company has a sizeable amount of $0.05 warrants in
the market and management has already received a number of exercise notices. In summary,
management expects to see a large increase in its cash balance by year-end with a greatly reduced
outstanding debt balance.
Management plans to use increased cash position to execute on a more aggressive growth plan in
Germany and the Netherlands. The Company is in the final stages of adding additional Medical
Cannabis lines and has already started negotiations to add to its product offering to pharmacies
narcotics lines outside of the Cannabis space. Management will look to add more salespeople in country
and to accelerate activities to add more product lines to build out a larger and more diversified
pharmaceutical distribution company, which we expect to include pharmaceutical psychedelic products
as they become legally available in Germany.
In the Netherlands, the Company is continuing to advance on building out and launching its online
psychedelics retail platform. We have also shortlisted locations for a flagship store in Amsterdam.
Management will use increased liquidity to accelerate growth plans in 5 follow on cities in the country and
has will contemplate strategic moves to vertically integrate and broaden out its psychedelics business
model in The Netherlands before expanding into other countries.
PHARMADRUG INC. PROPOSES A STRATEGIC MUTUAL INVESTMENT WITH
RED LIGHT HOLLAND CORP
https://webfiles.thecse.com/200715_Press_release_Red_Light.pdf?CJs0Df7tX64974GxewFG.wWJOptbyYvo
Toronto, Ontario - (July 15, 2020) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the
“Company”) is pleased to announce that it has entered into a share exchange agreement with Red Light
Holland Corp. ("RLH") (CSE:TRIP), an Ontario-based corporation positioning itself to engage in the
production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the
Netherlands.
The two companies recognize the complimentary nature of their respective business models in the Dutch
psychedelic market and will seek to collaborate on strategic initiatives. RLH’s strategy to be a premier
grower of psychedelic truffles with microdose packaging fits well with Super Smart’s vision of elevating the
Smart Store experience by introducing new products and an educational approach. The two companies
plan to develop and foster a new market segment that seeks to use psilocybin to either attempt to potentially
treat medical conditions holistically or to increase cognitive performance. On a combined basis, the two
companies believe they can better execute on educating the market and increasing the profile of
psychedelics and psilocybin in The Netherlands at first followed by other markets as they open up.
Chairman and CEO of PharmaDrug said “I am extremely excited by this motion to cooperate and I look
forward to working closely with Todd (CEO and Director of RLH) to find ways to disrupt and expand the
market in psychedelics”.
Under the terms of the agreement, the Company will issue 9,333,333 units to RLH (the "PharmaDrug Units”)
at a price of $0.075 per PharmaDrug Unit, and RLH will issue 4,242,424 units (the "RLH Units") to the
Company. Each PharmaDrug Unit will consist of (i) one common share of PharmaDrug, (ii) 0.9 of a
PharmaDrug common share purchase warrant, with each whole warrant entitling the holder thereof to
acquire one common share of the Company at a price of $0.13 until 48 months after the issuance of the
warrants, and (iii) 0.1 of a PharmaDrug common share purchase warrant, each whole warrant entitling the
holder thereof to acquire one common share of PharmaDrug at a price of $0.08 until 48 months after the
issuance of the warrants. In addition, RLH subscribed for $200,000 of units of the Company, at a price of
$0.075 per unit, each unit consisting of (i) one common share of PharmaDrug, and (ii) one PharmaDrug
common share purchase warrant, each warrant entitling the holder thereof to acquire one common share
of PharmaDrug at a price of $0.08 until the date that is 48 months after the issuance of the warrants.
Each RLH Unit will consist of one common share in the capital of RLH (a “RLH Share”) and one RLH Share
purchase warrant (a “RLH Warrant”). Each RLH Warrant will entitle the holder to purchase one additional
RLH Share at an exercise price of $0.26 at any time until the date that is 48 months following its issuance,
subject to an accelerated expiry option. If, following the date that is four months and one day following the
date hereof, the volume weighted average trading price of the RLH Shares on the Canadian Securities
Exchange (the “CSE”) for any 10 consecutive trading days equals or exceeds $0.50, RLH may, upon
providing written notice to the holders of RLH Warrants, accelerate the expiry date of the RLH Warrants to
the date that is 30 days following the date of such written notice.
The Company intends to use the proceeds of the $200,000 investment for working capital and general
corporate purposes.
All securities of the Company issued pursuant to the above transaction are subject to a four-month hold
period under applicable securities laws expiring four months and one day after the closing.
Closing of the transaction is anticipated to occur on or about July 16, 2020.
Pharmadrug Provides Corporate Update and Balance Sheet Status
8:38 am ET December 15, 2020 (Newsfile) Print
Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to provide an update to the status of its balance sheet following the recent general equity market upswing and the increase in PharmaDrug's volume and share price appreciation.
Recent market activity has served to significantly strengthen PharmaDrug's balance sheet and improve its ability to execute on its current business plan. The market has contributed to increased balance sheet strength is four distinct ways. Firstly, PharmaDrug was able to raise in excess of $850,000 by selling marketable securities that the Company valued on its Q3 financials at $200,000, due to a subsequent increase in the value of the shares. Secondly, the Company holds 4.24 million shares of Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC:TRUFF), of which it has not yet sold any shares. The Company also holds 4.24 million warrants of Red Light Holland exercisable at a price of $0.26 per share. Thirdly, the Company is now receiving conversion notices of its outstanding debentures which have a conversion feature at $0.05 per share. As a result, the Company has already seen a material decrease in its outstanding debt since Q3 financials. We will update the market on the debenture principal outstanding prior to year-end. Lastly, the company has a sizeable amount of $0.05 warrants in the market and management has already received a number of exercise notices. In summary, management expects to see a large increase in its cash balance by year-end with a greatly reduced outstanding debt balance.
Management plans to use increased cash position to execute on a more aggressive growth plan in Germany and the Netherlands. The Company is in the final stages of adding additional Medical Cannabis lines and has already started negotiations to add to its product offering to pharmacies narcotics lines outside of the Cannabis space. Management will look to add more salespeople in country and to accelerate activities to add more product lines to build out a larger and more diversified pharmaceutical distribution company, which we expect to include pharmaceutical psychedelic products as they become legally available in Germany.
In the Netherlands, the Company is continuing to advance on building out and launching its online psychedelics retail platform. We have also shortlisted locations for a flagship store in Amsterdam. Management will use increased liquidity to accelerate growth plans in 5 follow on cities in the country and has will contemplate strategic moves to vertically integrate and broaden out its psychedelics business model in The Netherlands before expanding into other countries.
About PharmaDrug Inc.
PharmaDrug Inc. is building an international controlled substance and natural medicine company with a focus on Europe. The Company owns 80% of Pharmadrug GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, an early-stage retail company focused on consolidating the fragmented Dutch smartshop market. Smartshops are retail establishments in The Netherlands that specialize in the sale of psychoactive substances including psychedelic truffles.
For further information, please contact:
Daniel Cohen, Chairman and CEO
dcohen@pharmadrug.co
(647) 202-1824
Ionic. Not Ignite.
There's sooooo many contingencies in that deal...that weed company will never get sold. And Lobe's not getting cash. Their getting shares of Ignite and Ignite isn't even trading right now(one of the necessary contingencies).
I see Lobe didn't waste any time taking advantage of the current hype smh.
20,000,000 more shares out at .078usd and warrants at .20usd.
https://webfiles.thecse.com/LOBE_PR_Dec_14_2020_NBPP_announcement_Final.pdf?YSG5qGrNXqUQPUqd7hdGlNNed0tGa0Go
The OS hasn't been updated to 185mm on OTC.com yet. Anybody have an updated float? OTC still lists the number from 2019.
+54% GREAT DAY!
That is just flat out incorrect information.
Nice volume today! Finally got some eyes.
Getting LSD vibes with these images:
https://www.instagram.com/p/B9kDBLNJmc7/
https://www.instagram.com/p/B7OhQ-vhmZk/
This is thee dumbest list of "accomplishments" I've ever seen. A needless and unnecessary "Space Force" isn't an "accomplishment".
The fact of the matter is Trump DESTROYED the cannabis industry by installing our known mortal enemy Jeff Sessions as AG. You're a joke defending Trump on a Weed board smh. You people really have short memories.
Sessions went on to kill the industry immediately in 2017 and 2018, with a series of press conferences and precisely aimed words targeting states with reformed cannabis laws and publicly operated cannabis companies. He rolled back DOJ memos that had guided policy during the Obama administration and sent several letters to Congress urging them to act on Cannabis companies that were compliant with state law.
The industry was making strides here and internationally and all of that stood still and took a few steps back because of Sessions, all while Trump stood by and did nothing. And he never ever had good things for the cannabis sector in mind, his 2nd AG pick would've been our 2nd sworn mortal enemy - Chris Christie!
ok thanks. Thanks you, Billytbone and sircoggs, gonna look up some info.
Well I can't refer to individuals on here but there's some misleading commentary, painting a picture of a loaded AS leading to an overnight RS. All of these changes would be announced beforehand. What you decide to do after the announcement is up to each person.
You just stated his shares and voting rights...By continuing the voting argument you're sustaining my initial statement. Keep going please. Again, the CEO can not raise the company's AS by just a thought and "stroke of a pen". It'd need to be announced and voted on. During that time, anyone is free to sell/buy shares.
ok great, thanks for agreeing with me, that it would first need to be announced and then voted on. Thanks for agreeing.
The share count was updated last Friday morning after the 2 billion deal announcement. OS went from 1,495,998,259 shares to 1,682,478,259. If you're in this stock you should be aware of that.
Also an AS raise would have to be first announced and then voted on.
Yeah could be. I always expected Cronos to be Altria's "cannabis division" or something. Just gotta wait out the politics and then they'll take over. I see Adler still has alotta shares left. Gorenstein not so much. Probably have a ton of options tho.
Can't say for sure but for all we know, Gorenstein and Adler could be on the way out.
This looks like the real deal! Glad I jumped in, didn't want to miss out.
Yeah and plus, the clowns at Motley Fool hate Cronos! Over the years, they never missed an opportunity to criticize or disparage Cronos, always highlighting other LP's expansion efforts. Their whole metric of valuing LPs was based solely on volume and grow op space but we all see now that was a mistake and Cronos had it right all along. Since then, all of the LPs Motley Fool praised have suffered, gone thru Reverse splits and have had to write off or cease their massive buildout projects. Cronos has the best thing available - cold hard cash in their bank account. As long as we don't have management self dealing or squandering the money we'll be great. And I've been hearing great things about the Happy Dance line. Can't wait till we get federal medical, federal decriminalization (on the path to legalization) and 240e rescinded.
LOL
Remember when we were a minority holder of Hydropothecary and then they went public as Hexo. Then we sold our shares of them and made millions. All that info is just about as relevant as that old ass article.
You're welcome. Are you the real Pinky? Lol
oh please. Go away.
I remember Bedrocan! Missed out on that one but bought into Cronos for .77usd when it was PRMCF on the OTC. Alotta great opportunities in the weedsector before Trump and Sessions messed everything up. Hopefully we get back to that.
Yesterday's email said:
The number of shares you currently have will not change due to the Transaction.
Trading is anticipated to recommence in the coming days under the new ticker symbol BRCK.U on the CSE, subject to the CSE’s approval.
The recommencement of trading on the CSE is a requirement to re-list on the OTCQX. Once we recommence trading on the CSE, we will seek approval to be re-listed on the OTCQX, and we will send another update related to that re-listing when a date is provided by the OTC.
So this is frustrating. Anytime we approach a pps of .38 it sells off. Because this is a Canadian company and the Canadian investors are selling off at .50CAD which is .38USD. smh. I kept running into this with MindMed earlier this year and eventually just gave up. We'll need a massive push to get the Canadians to stop selling at their .50 cent level.
Nothing to do with Relief Therapeutics. This news is for a non-COVID drug from NeuroRX. NeuroRX is a totally different entity, hired by Relief to run trials in America. They have some management overlap but it's a totally different company that is not publicly traded.
A CEO shouldn't be concerned with the day to day PPS swings. A CEO's job is to steer the company and make sure their mission is accomplished(management, financing, acquistions etc). They're not there to keep PPS up or answer to OTC investors.
That said, this company doesn't have a CEO. Raghuram Selvaraju is the Chair of the board. The fact this company doesn't have a CEO should've raised a flag.
All Psychedelic initiatives passed!
Oregon and DC will effectively decriminalise psychedelics for 5 million people following successful ballot initiatives.
— Psychedelic Alpha (@Psyched_Alpha) November 4, 2020
OR Measure 109: Legalises Psilocybin Therapy
OR Measure 110: Decriminalises Drugs
DC Initiative 81: Decriminalises Psychedelics pic.twitter.com/gbeJAi8hhK